| Omega-3-carboxylic acids (Epanova) (Epanova) | AstraZeneca | Peroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptor | Atherosclerotic Cardiovascular Disease | Ph 3 | AstraZeneca's cardiovascular-outcomes trial of Epanova (STRENGTH) was stopped early for futility, and the company's last registered Epanova study (a Phase 1 study in China) completed in 2018 with nothing registered since -- consistent with AstraZeneca having discontinued the Epanova program. | source ↗ |
| Omega-3-carboxylic acids (Epanova) (Epanova) | AstraZeneca | Peroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptor | Crohn's Disease | Ph 3 | The Crohn's programme is historical: this candidate's occurrence NCT00074542 (Tillotts Pharma AG, Phase 3) is completed with no later Crohn's study registered, and the drug's persisted profiles record AstraZeneca's discontinuation of Epanova after STRENGTH was stopped for futility. | source ↗ |
| Omega-3-carboxylic acids (Epanova) (Epanova) | AstraZeneca | Peroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptor | Hypertriglyceridemia | Ph 3 | AstraZeneca's cardiovascular-outcomes trial of Epanova (STRENGTH) was stopped early for futility, and the company's last registered Epanova study (a Phase 1 study in China) completed in 2018 with nothing registered since -- consistent with AstraZeneca having discontinued the Epanova program. | source ↗ |
| Omega-3-carboxylic acids (Epanova) (Epanova) | AstraZeneca | Peroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptor | Severe Hypertriglyceridemia | Ph 2/3 | AstraZeneca's cardiovascular-outcomes trial of Epanova (STRENGTH) was stopped early for futility, and the company's last registered Epanova study (a Phase 1 study in China) completed in 2018 with nothing registered since -- consistent with AstraZeneca having discontinued the Epanova program. | source ↗ |
| Omega-3-carboxylic acids (Epanova) (Epanova) | AstraZeneca | Peroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptor | MASH / NASH | Ph 2 | EfficacyThis is AstraZeneca's Epanova (omega-3 carboxylic acids), developed for severe hypertriglyceridemia rather than NASH/MASH. AstraZeneca terminated Epanova's major Phase 3 outcomes trial (STRENGTH) in 2020 for futility and has since discontinued the product in the US, with no active MASH/NASH-specific program. | source ↗ |